This page shows the latest asthma drug news and features for those working in and with pharma, biotech and healthcare.
Amgen’s novel drug offers hope to the one-in-five people with severe asthma who also have nasal polyps. ... Amgen has announced new data showing its first-in-class asthma drug tezepelumab reduced exacerbations and improved lung function in patients
Drug 'has the potential to transform treatment for a broad population of severe asthma patients'. ... The US Food and Drug Administration (FDA) has accepted AstraZeneca (AZ) and Amgen’s submission for their investigational asthma drug tezepelumab and
AstraZeneca (AZ) and Amgen have submitted a biologic license application (BLA) for their first-in-class asthma drug tezepelumab to the US Food and Drug Administration (FDA). ... In September 2018, tezepelumab scored a breakthrough therapy designation (BTD
Drug is approved for asthma and other allergic and inflammatory conditions. ... This includes a number of allergic and inflammatory conditions, including moderate-to-severe persistent allergic asthma, chronic idiopathic urticaria (CIU) and nasal polyps.
Inhaled budesonide – a type of corticosteroid medication – is commonly used to treat asthma and chronic obstructive pulmonary disease. ... The inhaled asthma drug was given to 751 people within the first two weeks of symptom onset, while 1, 028 were
an asthma drug. ... In September 2018, tezepelumab scored a breakthrough therapy designation (BTD) from the US Food and Drug Administration (FDA) in patients with severe asthma without an eosinophilic phenotype.
More from news
Approximately 2 fully matching, plus 127 partially matching documents found.
You would imagine coronavirus would be one of those threats.”. GSK is trialling its biologic anti IL-5 drug mepolizumab, licensed for severe asthma, in eosinophilic COPD with a new phase ... The company is also forging ahead with biologics research in
This was the turning point for the development programme.”. The late nights interrogating the science and unpicking data sets prompted the switch from a drug for the broad asthma community to ... a therapy targeted at a subtype representing around 10%
Researchers are now trying to identify biomarker-based subgroups and drug combinations to try to improve therapeutic outcomes for patients. ... up innate immune responses, and Cancer Research UK is repurposing an AZ chemokine CCR4 receptor drug (AZD2098)
In fact, it’s safe to say most C-suite drug executives would hardly shed a tear upon news of Obamacare’s swift demise. ... To cite just one example, patients with financial need get an 85% discount on the popular asthma drug Advair, and that’s by
In April 2013, Novartis was denied patent protection for its cancer drug, Glivec, by the Indian Supreme Court. ... This follows similar patent defeats in India for Pegasys, Roche's hepatitis drug, Merck's asthma treatment, Singulair, Gilead's Viread (HIV)
More from intelligence
Approximately 0 fully matching, plus 5 partially matching documents found.
He joins the drug discovery firm from Xention Discovery, where he had served as chief scientific officer since co-founding the company in 2002. ... Discovery. Dr Peter Finan, chairman of Enterprise Therapeutics, said: “John's experience in ion channels,
the past year, and to develop new products in order to offset the decline of its best-selling asthma drug, Advair, as part of his new remit.
More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.
Redbow Consulting Group is a specialist healthcare management consultancy specialising in business strategy and marketing...